Futura's ED treatment gel receives approval in Saudi Arabia

Published: 14-Aug-2023
Distribution Manufacturing Regulatory

Futura Medical's distribution partner Labatec Pharma has received received regulatory approval for MED3000, the gel-based ED treatment, in Saudi Arabia

Pharmaceutical company Futura Medical has announced that its distribution partner Labatec Pharma has received regulatory approval for MED3000, Futura's innovative topical, gel-based Erectile Dysfunction (ED) treatment, in the Kingdom of Saudi Arabia.

Labatec will exclusively launch and commercialise MED3000 under the brand name Eroxon, with initial launch planned in Q4 2023. The manufacturing of Eroxon for the launch has been completed and it will be supported by a full marketing campaign. Saudi Arabia is one of the top ten ED markets in the world by value, with a reported 10.45% of married males experiencing ED.

Labatec will hold a launch symposium showcasing Eroxon at the 20th Urological Association of Asia Congress 2023, which is being held from 28 September to 1 October in conjunction with the 12th Emirates International Urological conference in Dubai, United Arab Emirates.

Regulatory approval in the Kingdom of Saudi Arabia paves the way for Eroxon to improve the lives of ED patients in this key market

- James Barder, CEO of Futura

Futura is establishing a growing network of licencing and distribution partners and continues to strengthen its position, with regulatory approval having now been granted in six Middle Eastern countries, including the Kingdom of Saudi Arabia and the United Arab Emirates. Regulatory approval in the Kingdom of Saudi Arabia closely follows Futura's recent European and UK launch of Eroxon and the FDA's approval of MED3000 in the USA as the first clinically proven gel for the treatment of ED available without a doctor's prescription.

James Barder, CEO of Futura said: "Regulatory approval in the Kingdom of Saudi Arabia paves the way for Eroxon to improve the lives of ED patients in this key market. Eroxon is a game changer in the ED space with its rapid speed of onset helping men get an erection within 10 minutes. This approval comes at a pivotal time for the company, as we continue to grow and expand the availability of MED3000 globally by building out our licensing and distribution network."

  • Companies:
  • Futura Medical
See more

You may also like

Distribution

Futura expands partnership with M8 Pharmaceuticals for remainder of Central and South American region

Read more
Futura Medical is pleased to announce that M8 Pharmaceuticals has taken up its rights to extend its licensing agreement from Brazil and Mexico to market MED3000 in a further 14 countries throughout the Central and South American region

Trending Articles

  1. Agilent boosts contract manufacturing capabilities with acquisition of BIOVECTRA The CDMO acquisition will bolster Agilent's end-to-end production capabilities in a number of popular therapeutics, including GLP-1 medications and ADCs
  2. Currax to build novel anti-obesity treatment production facility amidst GLP-1 supply issues The manufacturing facility will be dedicated to the production of anti-obesity drug Contrave, and will double its output in the EU and EEA
  3. Navigating biologics chemistry, manufacturing and controls with an innovative CDMO Drug development is a journey. From the initial discovery of a druggable target through to commercialisation, biopharma companies face an uphill battle when designing, optimising and advancing safe and efficacious drugs
  4. GSK licenses Touchlight's enzymatic dbDNA for optimised mRNA vaccine production GSK will now have non-exclusive rights to the use of dbDNA for efficient commercial DNA and mRNA production
  5. Tabletability, compactability and compressibility: What’s the difference? To patients and consumers, tablets are a simple and convenient dosage form, but the science behind compressing a block of particles or granules into a single tablet can be complicated. Here, the tablet experts Natoli explain how to develop tabletability, compactibility, and compressibility profiles

Upcoming event

ISPE Singapore

28-30 August 2024 | Conference and exhibition | Singapore See all

You may also like

Distribution

Futura expands partnership with M8 Pharmaceuticals for remainder of Central and South American region

Futura Medical is pleased to announce that M8 Pharmaceuticals has taken up its rights to extend its licensing agreement from Brazil and Mexico to market MED3000 in a further 14 countries throughout the Central and South American region
Regulatory

Carbogen Amcis completes two FDA inspections at its Swiss API R&D and manufacturing facilities

The company's Neuland and Aarau sites specialise in API research and development, as well as cGMP manufacturing and analytics
Regulatory

Novo Nordisk's Wegovy gains positive opinion from the EMA for cardiovascular event risk reduction

The GLP-1 medication has proven effective at reducing the risk of major adverse cardiovascular events in adults with established cardiovascular disease
Manufacturing

Almac’s Charnwood facility receives FDA approval for oral dose development and manufacturing

The facility, which focuses on the manufacture of high potency oral dosage forms, has been approved for use by the FDA
Regulatory

Tiziana Life Sciences receive FDA fast track for anti-CD3 mAb to treat MS

The designation will allow Tiziana to receive priority in the review and approval process, allowing for the accelerated commercialisation of intranasal foralumab
Manufacturing

Process development and clinical manufacturing

Process development & cGMP contract manufacturing for biologics and cell therapies
Manufacturing

KBI Biopharma extends contract with a big pharma giant after a successful FDA inspection

The contract has been renewed and extended until at least 2029, and will now include the purchase of two therapeutic products
Subscribe now